Skip to main content
MANE
NYSE Life Sciences

Veradermics Reports Q1 Results, $862.8M Pro Forma Cash & Runway into 2030

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$111
Mkt Cap
$4.453B
52W Low
$32
52W High
$117.71
52W Position info
247% above low
Off High info
5.7% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MANE has more than doubled off its 52-week low of $32.

Summary

Veradermics reported Q1 financials, confirming a strong pro forma cash position of $862.8 million, extending its operational runway into 2030, and reiterated positive clinical trial progress for VDPHL01.


Key Events · Financing and Capital Events · MANE

  • Strong Financial Position

    Veradermics reported $390.8 million in cash, cash equivalents, and marketable securities as of March 31, 2026. Subsequent to quarter-end, the company completed a follow-on offering, raising approximately $472.0 million in gross proceeds, resulting in approximately $862.8 million in pro forma cash.

  • Extended Cash Runway

    The company expects its current capital to fund operations into 2030, covering multiple anticipated Phase 3 readouts and the potential commercial launch of VDPHL01, if approved.

  • Q1 2026 Financials

    Net loss for the first quarter of 2026 was $27.2 million, an increase from $12.4 million in the first quarter of 2025, primarily due to increased research and development ($20.9M vs $11.4M) and general and administrative expenses ($8.9M vs $1.5M).

  • Clinical Trial Progress

    The company reiterated positive topline data from its Phase 2/3 Study '302' for VDPHL01, announced completion of enrollment for Study '304', and reported ongoing enrollment for Study '306', with key data readouts expected in the second half of 2026.


Analysis · MANE · Life Sciences

This 8-K details Veradermics' first-quarter financial results, highlighting a significantly strengthened balance sheet with approximately $862.8 million in pro forma cash and cash equivalents. This capital is expected to fund operations into 2030, providing a long runway through multiple Phase 3 readouts and potential commercial launch of VDPHL01. The report also reiterates positive Phase 2/3 clinical data for VDPHL01 and progress on other trials, with key data milestones anticipated in the second half of 2026. This financial stability is critical for a clinical-stage biopharmaceutical company.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MANE was trading at $111.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $32.00 to $117.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MANE - Latest Insights

MANE
Nov 13, 2026, 5:39 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $129.66
Real-time Price: $118.49 info
Change: -$11.17 (-9%) info
Market Cap: $5.043B info
MANE
Nov 10, 2026, 4:57 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $148.44
Real-time Price: $118.49 info
Change: -$29.95 (-20%) info
Market Cap: $5.043B info
MANE
Nov 10, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $142.72
Real-time Price: $118.49 info
Change: -$24.23 (-17%) info
Market Cap: $5.043B info
MANE
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $142.00
Real-time Price: $118.49 info
Change: -$23.51 (-17%) info
Market Cap: $5.043B info
MANE
Nov 08, 2026, 6:00 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $139.33
Real-time Price: $118.49 info
Change: -$20.84 (-15%) info
Market Cap: $5.043B info